Search Within

Min Yuen Teo

  1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Meeting Abstract (35)
  2. Journal Article (20)
  3. Editorial (1)
Groups
  1. Department of Medicine (56)
  2. Department of Pathology and Laboratory Medicine (56)
  3. Genitourinary Oncology Service (56)
  4. Solid Tumor Oncology Division (56)
  5. Human Oncology and Pathogenesis Program (42)
  6. Surgery (42)

More Groups

People
  1. Gopakumar Iyer (53)
  2. Hikmat Al-Ahmadie (50)
  3. Jonathan Rosenberg (50)
  4. Dean Bajorin (48)
  5. David Solit (38)
  6. Samuel Funt (36)

More People

Years
  1. 2025 (1)
  2. 2024 (6)
  3. 2023 (4)
  4. 2022 (10)
  5. 2021 (7)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (28)
  2. Cancer Research (4)
  3. Modern Pathology (4)
  4. Clinical Cancer Research (3)
  5. Laboratory Investigation (3)
  6. European Urology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (30)
  2. American Association for Cancer Research (7)
  3. Nature Publishing Group (6)
  4. Nature Research (4)
  5. Cell Press (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (56)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
    Journal Article

    Nguyen, B.; Fong, C.; Luthra, A.; Smith, S. A.; DiNatale, R. G.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Madupuri, R.; Kundra, R.; more...
    Cell (2022)

    Fulltext@MSK | Save
  • CD274 (PD-L1) copy number changes (gain) & response to immune checkpoint blockade therapy in carcinomas of the urinary tract
    Journal Article

    Gupta, S.; Vanderbilt, C. M.; Zhang, Y.; Tickoo, S. K.; Fine, S. W.; Gopalan, A.; Chen, Y. B.; Sirintrapun, S. J.; Teo, M. Y.; Funt, S. A.; more...
    Bladder Cancer (2021)

    Fulltext@MSK | Save
  • Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial
    Meeting Abstract

    Funt, S. A.; Lattanzi, M.; Whiting, K.; Al-Ahmadie, H. A.; Quinlan, C.; Teo, M. Y.; Kamradt, J.; Khalil, M. F.; Ostrovnaya, I.; McCoy, A. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Detection of FGFR3 alt in plasma cfDNA in metastatic UC patients receiving Erda therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Lenis, A. T.; Chen, Z.; Al-Ahmadie, H. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience
    Meeting Abstract

    Guercio, B. J.; Gandhi, J.; Teo, M. Y.; Lattanzi, M.; Funt, S. A.; Aggen, D. H.; Chen, Y. B.; Fine, S.; Pietzak, E. J.; Bochner, B. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma
    Meeting Abstract

    Teo, M. Y.; McBride, S.; Gopalan, A.; Benoliel, H.; Eastham, J. A.; Goh, A.; Szmulewitz, R.; Morgans, A. K.; Bubley, G.; Gupta, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma
    Journal Article

    Teo, M. Y.; Al-Ahmadie, H.; Seier, K.; Tully, C.; Regazzi, A. M.; Pietzak, E.; Solit, D. B.; Tickoo, S.; Reuter, V.; Cha, E. K.; more...
    British Journal of Cancer (2021)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
    Journal Article

    Sarfaty, M.; Whiting, K.; Teo, M. Y.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; Jungbluth, A. A.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • MSK-ACCESS for the detection of fibroblast growth factor receptor-3 (FGFR3) mutations in plasma cell-free (cf)DNA of metastatic urothelial carcinoma (mUC) patients (pts) pre- and on erdafitinib (erda) therapy
    Meeting Abstract

    Sarfaty, M.; Teo, M. Y.; Funt, S. A.; Lee, C. H.; Aggen, D. H.; Ratna, N.; Regazzi, A. M.; Al-Ahmadie, H.; Brannon, A. R.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma
    Journal Article

    Teo, M. Y.; Mota, J. M.; Whiting, K. A.; Li, H. A.; Funt, S. A.; Lee, C. H.; Solit, D. B.; Al-Ahmadie, H.; Milowsky, M. I.; Balar, A. V.; more...
    European Urology (2020)

    Fulltext@MSK | Save